Sinocelltech Group Ltd (688520) - Total Liabilities

Latest as of September 2025: CN¥4.49 Billion CNY ≈ $657.34 Million USD

Based on the latest financial reports, Sinocelltech Group Ltd (688520) has total liabilities worth CN¥4.49 Billion CNY (≈ $657.34 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Sinocelltech Group Ltd - Total Liabilities Trend (2016–2024)

This chart illustrates how Sinocelltech Group Ltd's total liabilities have evolved over time, based on quarterly financial data. See Sinocelltech Group Ltd working capital to net assets to evaluate short-term liquidity relative to the company's equity base.

Sinocelltech Group Ltd Competitors by Total Liabilities

The table below lists competitors of Sinocelltech Group Ltd ranked by their total liabilities.

Company Country Total Liabilities
Boardwalk Real Estate Investment Trust
TO:BEI-UN
Canada CA$4.11 Billion
Teekay Tankers Ltd
NYSE:TNK
USA $181.93 Million
Greentown China Holdings Limited
F:G7C
Germany €398.79 Billion
TES Co. Ltd
KQ:095610
Korea ₩128.46 Billion
Affle (India) Limited
NSE:AFFLE
India Rs6.58 Billion
Prestige Brand Holdings Inc
NYSE:PBH
USA $1.66 Billion
Visual China Group Co Ltd
SHE:000681
China CN¥766.48 Million
Western Union Co
NYSE:WU
USA $7.19 Billion

Liability Composition Analysis (2016–2024)

This chart breaks down Sinocelltech Group Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Sinocelltech Group Ltd (688520) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.61 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -6.20 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.19 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Sinocelltech Group Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Sinocelltech Group Ltd (2016–2024)

The table below shows the annual total liabilities of Sinocelltech Group Ltd from 2016 to 2024.

Year Total Liabilities Change
2024-12-31 CN¥3.15 Billion
≈ $460.81 Million
-5.27%
2023-12-31 CN¥3.32 Billion
≈ $486.46 Million
+11.63%
2022-12-31 CN¥2.98 Billion
≈ $435.78 Million
+85.64%
2021-12-31 CN¥1.60 Billion
≈ $234.74 Million
+49.21%
2020-12-31 CN¥1.08 Billion
≈ $157.33 Million
+39.02%
2019-12-31 CN¥773.39 Million
≈ $113.17 Million
+37.22%
2018-12-31 CN¥563.60 Million
≈ $82.47 Million
+76.62%
2017-12-31 CN¥319.10 Million
≈ $46.69 Million
-6.50%
2016-12-31 CN¥341.30 Million
≈ $49.94 Million
--

About Sinocelltech Group Ltd

SHG:688520 China Biotechnology
Market Cap
$2.23 Billion
CN¥15.21 Billion CNY
Market Cap Rank
#5962 Global
#1231 in China
Share Price
CN¥34.16
Change (1 day)
+2.95%
52-Week Range
CN¥33.12 - CN¥85.63
All Time High
CN¥101.80
About

Sinocelltech Group Limited, a biopharmaceutical company, engages in the research, development, and production of recombinant proteins, antibody drugs, and vaccines in China. The company offers Anjiayin, a third-generation recombinant coagulation factor VIII product for the treatment of hemophilia A; Anpingxi, an anti-CD20 monoclonal antibody for the treatment of CD20-positive diffuse large B-cell… Read more